|
|
|
|
| LEADER |
02249nmm a2200337 u 4500 |
| 001 |
EB001492269 |
| 003 |
EBX01000000000000000921858 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
170703 ||| eng |
| 020 |
|
|
|a 9783319596594
|
| 100 |
1 |
|
|a Bauersachs, Johann
|e [editor]
|
| 245 |
0 |
0 |
|a Heart Failure
|h Elektronische Ressource
|c edited by Johann Bauersachs, Javed Butler, Peter Sandner
|
| 250 |
|
|
|a 1st ed. 2017
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2017, 2017
|
| 300 |
|
|
|a IX, 581 p. 100 illus., 30 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Introduction -- Epidemiology -- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine -- Beta3 agonists -- Novel MRAs -- pGCs and Natriuretic peptides -- sGC stimulators -- PDE’s -- Adenosin and A1 Agonists -- Myosin heavy chain / Troponin -- Stem cells -- Diuretics and Vasopressin -- GeneTherapy -- RNA-based therapies and micro RNAs -- Cardiac myosin activation using gene therapy -- Bendavia – mitochondrial therapies -- WNT signaling -- Anticoagulation therapy and NOACS in HF -- Potassium Binders -- Iron.
|
| 653 |
|
|
|a Human Physiology
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Human physiology
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Pharmacology/Toxicology
|
| 700 |
1 |
|
|a Butler, Javed
|e [editor]
|
| 700 |
1 |
|
|a Sandner, Peter
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-59659-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|
| 520 |
|
|
|a This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment
|